828242-83-7

Upstream product

• 1220198-08-2 (2-bromo-ethoxy)-tert-butyl-dimethyl-silane 
• 100-83-4 meta-hydroxybenzaldehyde 
• 86864-60-0 2-(tert-butyldimethylsilyloxy)ethyl bromide 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 60345-97-3 3-(2-hydroxyethoxy)benzaldehyde 

Downstream Products

• 60345-97-3 3-(2-hydroxyethoxy)benzaldehyde 
• 1246251-42-2 2-(3-(2-hydroxyethoxy)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one 
• 1621132-91-9 C₃₂H₂₄N₄O₇ 
• 1621132-85-1 C₄₃H₃₂N₄O₈ 
• 1621132-90-8 3-(2-azidoethoxy)-N-hydroxybenzencarboximidoyl chloride 
• 1621132-89-5 3-(2-azidoethoxy)benzaldehyde oxime 
• 1621132-88-4 3-(2-azidoethoxy)benzaldehyde 
• 186191-19-5 m-(2-bromoethyloxy)benzaldehyde 

Relevant academic research and scientific papers

Anti-inflammatory agents

Disclosed are novel compounds that are useful in regulating the expression of interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1), and their use in the treatment and/or prevention of cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s). Also, disclosed are compositions comprising the novel compounds, as well as methods for their preparation.

Contrast agent and for the use of a synthetic composition, method and system (by machine translation)

The present invention provides compounds with imaging moieties for imaging a subject. The present invention also relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, a composition or plurality of imaging agents is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs.

Photoactivatable fluorescein derivatives caged with a (3-hydroxy-2- naphthalenyl)methyl group

The (3-hydroxy-2-naphthalenyl)methyl (NQMP) group represents an efficient photocage for fluorescein-based dyes. Thus, irradiation of the 6-NQMP ether of 2'-hydroxymethylfluorescein with low-intensity UVA light results in a 4-fold increase in emission inte

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

ARYLAMINE-SUBSTITUTED QUINAZOLINONE COMPOUNDS

Compounds represented by Formula (I) which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R', R